Amylin (AMLN) Announces BYETTA Approved As Stand-Alone Medication
More News related to AMLN
- Notable Analyst Rating Changes 11/24: ABG, PRU, RS, AYI, AMLN, TLAB Upgraded; DELL, CIEN, UNP, ALV Downgraded
- Amylin Pharmaceuticals (AMLN): Upgraded to Overweight at Barclays, target raised to $22
- Barclays Upgrades Amylin Pharmaceuticals (AMLN) to Overweight
- Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
- Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDA's BYETTA(R) (Exenatide) Injection Update
More News related to LLY
- Trading Review for Vivus Inc. Issued by Beacon Equity
- VerifyNow(R) System Highlighted in POPular Study Comparing Platelet Reactivity Tests
- New Updates to AHA/ACC/SCAI Clinical Guidelines Recommend Treatment with Effient(R) for Patients with Acute Coronary Syndromes Managed with PCI
- Lilly Surpasses United Way 2009 Campaign Goal
- Effient(R) Exhibited Greater Antiplatelet Activity than High Dose Clopidogrel in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease
Over the weekend, Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that the FDA has approved an expanded indication for BYETTA injection.
BYETTA is now approved for use as a stand-alone medication along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Previously, it was approved for use only in patients who were also taking other common diabetes medications and had not achieved adequate glycemic control.
Related Categories
FDAStocks Mentioned
-0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
